Revance Therapeutics, Inc. ("Revance") today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures and new investor, NovaQuest Capital (NovaQuest). New investor, CNF Investments, also joined the syndicate which included participation from existing investors: Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corporation.
“We look forward to being a part of the Revance team as they continue further late-stage development to bring these novel compounds to market.”
Concurrent with the financing, Jonathan Tunnicliffe, Partner at NovaQuest will join the Revance Board of Directors. "The market for botulinum toxin neuromodulators is already very large and growing and we believe that the Revance technologies for the first topically applied dose form and next generation injectable product are highly differentiated from current offerings and will expand the market further." Mr. Tunnicliffe continued, "We look forward to being a part of the Revance team as they continue further late-stage development to bring these novel compounds to market."
"We are pleased that NovaQuest is joining Essex Woodlands and our existing syndicate," said Dan Browne, President and CEO of Revance. "Their combined expertise will be an invaluable asset as Revance develops its topical and injectable neuromodulation pipeline in both aesthetic and therapeutic categories."